UPDATE: Citigroup Reduces PT to $49 on Teva Pharmaceuticals on Lower Estimates

Citigroup reduces its price target fro $55 to $49 on Teva Pharmaceuticals TEVA as it reiterates shares at Buy. Citigroup notes, "We lowered our 2012E EPS on TEVA by (-$0.28) to $5.40 (+9%) compared to TEVA's rebased 2012E EPS range of $5.30(+7%)-$5.40(+9%) vs. the Street's $5.57 & below its previous $5.48 (+10%)-$5.68(+14%) on lower sales. Our 2012E sales decreased by (-$780M) to $20.5B vs. TEVA's $20.0B-$21.0B range. We lowered our 2013E & 2014E sales/EPS by (-$760M) & (-$790M) to $21.9B(+7%) & $23.2B(+6%) & (-$0.19) /( -$0.20) to $6.06(+12%)/$6.43 (+6%). Our 3-yr 2011-14E sales/EPS CAGR's decrease to +8%/+9% from +9%/ +10%." TEVA closed at $38.69 on Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetReiterationPre-Market OutlookAnalyst RatingsCitigroup
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!